LymeX Authorization Act

The LymeX Authorization Act (HR7482) was introduced in the House of Representatives on February 11, 2026, and subsequently referred to the House Committee on Energy and Commerce. This bill's current status is early stage, having only been introduced and referred to committee. The legislative process for this bill is in its initial phases, and it has not yet advanced beyond committee consideration. This legislation authorizes the Secretary of Health and Human Services to fund prize competitions totaling $5,000,000 to accelerate innovation in Lyme disease. It is crucial to note that this is an authorization, not an appropriation. The bill sets a spending ceiling and establishes the policy framework for these competitions, but actual funding would require a separate appropriations bill to be passed. Therefore, no immediate allocation of funds has occurred, and the $5,000,000 represents the maximum amount that could be appropriated for this purpose if the bill becomes law and subsequent appropriations are made. The primary beneficiaries of this bill, should it advance and receive appropriations, would be entities engaged in medical research and development, particularly those focused on infectious diseases, diagnostics, and therapeutics for Lyme disease. This includes academic institutions, non-profit research organizations, and biotechnology companies. Given the nature of prize competitions, smaller, innovative firms and startups could also be positioned to benefit. However, without specific appropriation, there are no immediate financial impacts or direct contracts to specific companies. No specific publicly traded companies are uniquely positioned at this early stage. As of April 7, 2026, the bill remains in committee. The next legislative steps would involve committee hearings, potential markups, and a vote to report the bill out of committee. If successful, it would then proceed to a vote by the full House. Given its early stage and the need for subsequent appropriation, the timeline for any market impact is extended and contingent on further legislative action.